

FORM PTO-1449 (Modified)

Attorney Docket No.
015280-325100Serial No.:
09/071,672LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

(Use several sheets if necessary)

Applicant: Susanna M. Rybak, et al.

Filing Date: May 1,
1998

Group: Unknown

Reference Designation

U.S. PATENT DOCUMENTS

| Examiner Initial | Document No. | Date | Name | Class | Sub-class | Filing Date (If Appropriate) |
|------------------|--------------|-----------|--------------------|-----------------|-----------|------------------------------------|
| AO | AA | 4,816,567 | 03/28/89 | Cabilly, et al. | 530 | 387 |
| AB | 5,559,212 | 09/24/96 | Wojciech J. Ardelt | 530 | 350 | — |
| AC | 5,728,805 | 03/17/98 | Wojciech J. Ardelt | 530 | 350 | — |

FOREIGN PATENT DOCUMENTS

| | Document No. | Date | Country | Class | Sub-class | Translation (yes/no) |
|----|------------------------------|----------|---------|---------|-----------|-------------------------|
| AD | EP 0 173 494 A2 | 07/08/85 | Europe | G12N-15 | 00 | Yes |
| AE | WO 87/02671 | 10/27/86 | PCT | C07H-15 | 12 | Yes |
| AF | WO 88/09344-A | 05/19/88 | PCT | C07K-13 | 00 | Yes |
| AG | WO 97/02588 | 06/20/96 | PCT | H01J-37 | 32 | Yes |
| AH | PCT/US98/05453 (as filed) | 03/19/98 | PCT | | | Yes |

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----|--|
| AI | De Prisco, et al., "A Ribonuclease from human seminal plasma active on double-stranded RNA, <i>Biochim. Biophys. Acta</i> 788:356-363 (1984) |
| AJ | Jones, et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> 321:522-525 (5/29/86) |
| AK | Williams, et al., "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment" <i>Gene</i> 43:319-324 (1986) |
| AL | St. Clair, et al., "Angiogenin abolishes cell-free protein synthesis by specific ribonucleolytic inactivation of ribosomes," <i>Proc. Natl. Acad. Sci. USA</i> 84:8330-8334 (12/87) |
| AM | Riechmann, et al., "Reshaping human antibodies for therapy," <i>Nature</i> 332:323-327 (3/24/88) |
| AN | Huston, et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 85:5878-5883 (8/88) |
| AO | Bird, et al., "Single-chain antigen-binding proteins," <i>Science</i> 242:423-426 (10/21/98) |
| AP | Darzynkiewicz, et al., "Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent," <i>Cell Tissue Kinet.</i> 21:169-182 (1988) |
| AQ | Khazaeli, et al., "Immunology," <i>Proceedings of AACR</i> 29:418 (1988) |
| AR | Nishimura, et al., "Expression and function of a CD 5 cDNA in human and murine T cells," <i>Eur. J. Immunol.</i> 18:747-753 (1988) |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | | |
|--|--|--------------------------------------|------|--|---------------------------------|
| FORM PTO-1449 (Modified) | | Attorney Docket No. 015280-325100 | | Serial No.: 09/071,672-9(886) <i>as</i> | |
| LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant: Susanna M. Rybak, et al. | | | |
| | | Filing Date: May 1, 1998 | | Group: Unknown 1644 | |
| Reference Designation | | U.S. PATENT DOCUMENTS | | | |
| Examiner Initial | Document No. | Date | Name | Class | Filing Date (If Appropriate) |
| OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | |
| <i>AS</i> | Griffin, et al., "Immunotoxin therapy: Assessment by animal models," <i>Immunotoxins</i> , Boston/Dordrecht/Lancaster, Kluwer Academic Publishers, p.433-455 (1988) | | | | |
| AT | Chaudhary, et al., "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> exotoxin," <i>Nature</i> 339:394-397 (6/1/89) | | | | |
| AU | Ward, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> 341:544-546 (10/12/89) | | | | |
| AV | Batra, et al., "Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of <i>Pseudomonas</i> exotoxin," <i>Proc. Natl. Acad. Sci. USA</i> 86:8545-8549 (11/89) | | | | |
| AW | Mikulski, et al., "Striking increase of survival of mice bearing M109 madison carcinoma treated with a novel protein from amphibian embryos," <i>J. Nat'l. Cancer Inst.</i> 82(2):151-153 (1/17/90) | | | | |
| AX | Chaudhary, et al., "A rapid method of cloning functional variable-region antibody genes in <i>Escherichia coli</i> as single-chain immunotoxins," <i>Proc. Natl. Acad. Sci. USA</i> 87:1066-1070 (2/90) | | | | |
| AY | Casadei, et al., "Expression and secretion of aequorin as a chimeric antibody by means of a mammalian expression vector," <i>Proc. Natl. Acad. Sci. USA</i> 87:2047-2051 (3/90) | | | | |
| AZ | Goodson, et al., "Site-directed pegylation of recombinant interleukin-2 at its glycosylation site," <i>Bio/Technology</i> 8:343-346 (4/90) | | | | |
| BA | Batra, et al., "Anti-tac(Fv)-PE40, a single chain antibody <i>Pseudomonas</i> fusion protein directed at interleukin 2 receptor bearing cells," <i>J. Biol. Chem.</i> 265:15198-15202 (9/5/90) | | | | |
| BB | Mikulski, et al., "Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumour activity," <i>Cell Tissue Kinet.</i> 23:237-246 (1990) | | | | |
| BC | Winter, et al., "Man-made antibodies," <i>Nature</i> 349:293-299 (1/24/91) | | | | |
| BD | Rybak, et al., "Human Cancer Immunology II. Clinical use of immunotoxins. Monoclonal antibodies conjugated to protein toxins," <i>Immunology and Allergy Clinics of North America</i> 11(2):359-380, W.B. Saunders Co. (5/91) | | | | |
| BE | Pearson, J.W., et al., "Reversal of Drug Resistance in a Human Colon Cancer Xenograft Expressing MDR1 Complementary DNA by in vivo administration of MRK-16 monoclonal Antibody," <i>J. Natl. Cancer Inst.</i> 83(19):1386-1391 (10/2/91) | | | | |
| <i>BF</i> | Ghetie, et al., "Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated Human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites," <i>Cancer Res.</i> 51:5876-5880 (11/1/91) | | | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Am De Puma 1-21-93

| | | | | | |
|--|--|--------------------------------------|------|---|-----------|
| FORM PTO-1449 (Modified) | | Attorney Docket No. 015280-325100 | | Serial No.: 09/071,672 09/918,887 | |
| LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant: Susanna M. Rybak, et al. | | | |
| | | Filing Date: May 1, 1998 | | Group: Unknown 1644 | |
| Reference Designation | | U.S. PATENT DOCUMENTS | | | |
| Examiner Initial | Document No. | Date | Name | Class | Sub-class |
| OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | |
| <u>41</u> BG | Hoogenboom, et al., "Construction and expression of antibody-tumor necrosis factor fusion proteins," <i>Molecular Immunology</i> 28(9):1027-1037 (11/4/91) | | | | |
| BH | Rybak, et al., "Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins," <i>J. Biol. Chem.</i> 266:21202-21207 (11/5/91) | | | | |
| BI | Hoogenboom, et al., "Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule," <i>Biochim. Biophys. Acta</i> 1096:345-354 (11/20/91) | | | | |
| BJ | Ardelt, et al., "Amino acid sequence of an anti-tumor protein from <i>Rana pipiens</i> oocytes and early embryos," <i>J. Biol. Chem.</i> 266(1):245-251 (1991) | | | | |
| BK | Uckun, et al., "In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human Pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency," <i>Blood</i> 79(9):2201-2214 (5/1/92) | | | | |
| BL | Newton, et al., "Cytotoxic ribonuclease chimeras," <i>J. Biol. Chem.</i> 267(27):19572-19578 (9/25/92) | | | | |
| BM | Grossbard, et al., "Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms," <i>J. Clin. Oncol.</i> 11(4):726-737 (4/93) | | | | |
| BN | Grossbard, et al., "Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma," <i>Blood</i> 81(9):2263-2271 (5/1/93) | | | | |
| BO | Amlot, et al., "A Phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy," <i>Blood</i> 82(9):2624-2633 (11/1/93) | | | | |
| BP | Rybak, et al. "Cytotoxic onconase and ribonuclease A chimeras: Comparison and in Vitro characterization," <i>Drug Delivery</i> 1:3-10 (1993) | | | | |
| BQ | Newton, et al., "Toxicity of an antitumor ribonuclease to Purkinje neurons," <i>J. Neurosci.</i> 14(2):538-544 (2/94) | | | | |
| BR | Rybak, et al., "RNase and RNase immunofusions for cancer therapy," <i>Tumor Targeting</i> 1(3):141-147 (1995) | | | | |
| BS | Francisco, et al., "Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen," <i>Cancer Res.</i> 55:3099-3104 (7/15/95) | | | | |
| BT | Sausville, et al., "Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A Phase I study," <i>Blood</i> 85(12):3457-3465 (6/15/95) | | | | |
| BU | Mansfield, et al., "Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies," <i>Bioconj. Chem.</i> 7:557-563 (1996) | | | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Am De Lem 1-21-03

| | | | | | |
|--|--|--------------------------------------|------|---|---------------------------------|
| FORM PTO-1449 (Modified) | | Attorney Docket No. 015280-325100 | | Serial No.: 09/071,672 09/918,867 | |
| LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant: Susanna M. Rybak, et al. | | | |
| | | Filing Date: May 1, 1998 | | Group: Unknown 1644 | |
| Reference Designation | | U.S. PATENT DOCUMENTS | | | |
| Examiner Initial | Document No. | Date | Name | Class | Filing Date (If Appropriate) |
| OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | |
| <input checked="" type="checkbox"/> BV | Newton, D.L., et al., "Anti-tumor ribonuclease, combined with or conjugated to monoclonal antibody MRK16, overcomes multidrug resistance to vincristine in vitro and in vivo," <i>Int'l. Oncology</i> 8:1095-1104 (1996) | | | | |
| <input type="checkbox"/> BW | Newton, D.L., et al., "Angiogenin single-chain immununofusions: influence of peptide linkers and spacers between fusion protein domains," <i>Biochemistry</i> 35:545-553 (1996) | | | | |
| <input type="checkbox"/> BX | Mansfield, et al., "Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors," <i>Blood</i> 90(5):2020-2026 (9/1/97) | | | | |
| <input checked="" type="checkbox"/> BY | Mansfield, et al., "Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells," <i>Biochem. Soc. Trans.</i> 25:709-714 (1997) | | | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1449.WP 4/95

Amend 1-21-03

F:\DATA\PS\PTOD\SKF\88543.1